Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

NG2 and DLL3 CAR-T Cells Targeting Melanoma

A legfontosabb adatok

Ki végzi
Shenzhen Geno-Immune Medical Institute
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
100 fő vett részt
Kezdés
2025. szept. 1.
Befejezés
2026. júl. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • NG2 and DLL3 CAR-T cells
A regiszteradat frissítve
2026. november 3.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (22)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Patients with tumors have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent conditions
  • The expression status of NG2 and DLL3 antigens of the tumor has been determined for eligibility. Positive expression is defined by NG2 and DLL3 antibody staining results based on immunohistochemistry or flow cytometry analyses
  • Body weight greater than or equal to 40 kg
  • Age: ≥18 year and ≤ 75 years of age at the time of enrollment
  • Life expectancy: at least 8 weeks
  • Prior Therapy:; There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less; Participants must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection; At least 7 days must have elapsed since the completion of therapy with any biologic agent, targeted agent, tyrosine kinase inhibitor or metronomic non-myelosuppressive regimen; At least 4 weeks must have elapsed since prior therapy that includes a monoclonal antibody; At least 1 week must has elapsed since any radiation therapy at the time of study entry
  • Karnofsky/jansky score of 70% or greater
  • Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent
  • Pulse Ox greater than or equal to 90% on room air
  • Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN
  • Renal function: Patients must have serum creatinine less than 3 times ULN
  • Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion)
  • Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease not evaluable for hematologic toxicity
  • For all patients enrolled in this study, their parents or legal guardians must sign an informed consent and assent

Ki nem vehet részt

  • Untreated central nervous system (CNS) metastasis; patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible
  • Previous treatment with other genetically engineered CAR T cells
  • Patients who require systemic corticosteroid or other immunosuppressive therapy
  • Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, with the exception of grade 3 hematologic toxicity
  • Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection
  • Evidence of tumor potentially causing airway obstruction
  • Inability to comply with protocol requirements
  • Insufficient availability of CART cells

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.

A vizsgálat csoportja

  • effectiveness of CAR-T cells targeting NG2 and DLL3A vizsgált kezelés

    Gene-modified T cells are designed to kill tumor cells through specific recognition of NG2 and DLL3. This study will evaluate the side effects and effective doses of NG2 and DLL3 CAR-T cells in treating refractory and recurrent melanoma

    Kezelés: NG2 and DLL3 CAR-T cells

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety and Efficacy of NG2 and DLL3 CAR-T Therapy Targeting Melanoma
A regiszteradat frissítve
2026. november 3.